WO1996035452A1 - Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders - Google Patents
Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders Download PDFInfo
- Publication number
- WO1996035452A1 WO1996035452A1 PCT/GB1996/001107 GB9601107W WO9635452A1 WO 1996035452 A1 WO1996035452 A1 WO 1996035452A1 GB 9601107 W GB9601107 W GB 9601107W WO 9635452 A1 WO9635452 A1 WO 9635452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- acetylcysteine
- expectorant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
Definitions
- This invention relates to a pharmaceutical composition.
- South African Patent Application No. 94/0155 describes and claims a pharmaceutical composition in unit dosage form which comprises a therapeutic dose of acetylcysteine or carbocysteine and a therapeutic dose of terbutaline or pharmaceutically acceptable salt thereof.
- the composition may be formulated as a capsule, tablet, synip, intravenous solution, nebulising solution, aerosol inhaler, dry powder inhaler or aqueous pump spray.
- the composition is useful in the treatment of respiratory tract disorders.
- South African Patents Nos. 92/1848 and 93/5931 describe simiiar pharmaceutical compositions, save that salbutamol or pharmaceutically acceptable salt thereof are used in place of terbutaline.
- composition comprising as active ingredients:
- the pharmaceutical composition of the invention will be provided in the form of dosage units with each unit containing each of the active ingredients.
- the dosage units may be capsules, tablets, syrups, intravenous solutions, nebulising solutions, aerosol inhalers, dry powder inhalers, or aqueous pump sprays.
- composition will provide each of the active ingredients in therapeutically effective amounts.
- the acetylcysteine, carbocysteine, erdosteine or pharmaceutically acceptable salt thereof will be present in an amount sufficient to produce a mucolytic action;
- the beta 2 agonist will be present in an amount sufficient to produce a bronchodilating action;
- the expectorant will be present in an amount sufficient to produce an expectorant action.
- the therapeutically effective amount of each active ingredient may be provided in a single dosage unit, e.g. a single tablet, teaspoon or intravenous unit, capsule, or may be provided in more than one dosage unit (multiple units), e.g. more than one tablet, capsule, teaspoon or intravenous unit.
- the preferred beta 2 agonist is terbutaline, salbutamol or a pharmaceutically acceptable salt thereof.
- the preferred expectorant is guaiphenesin.
- Other useful expectorants are sodium citrate and ammonium chloride.
- the pharmaceutical composition of the invention may be used in the treatment of respiratory tract disorders.
- the composition has particular use in treating coughs, bronchitis, or chronic pulmonary conditions such as emphysema, chronic bronchitis and bronchicetasis.
- the pharmaceutical composition will also contain one or more of the usual excipi ⁇ nts which are required to formulate the particular dosage unit.
- a preferred composition of the invention contains, as active ingredients, acetylcysteine or a pharmaceutically acceptable salt thereof , terbutaline pharmaceutically acceptable salt thereof / and guaiphenesin.
- a method of treatment of a human or animal patient suffering from a respiratory tract disorder comprising administering to said patient: (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and (b) a beta 2 agonist; and (c) an expectorant.
- the active ingredients are preferably each administered in a therapeutically effective amount.
- Acetylcysteine 100-2000mg Terbutaline sulphate l-5mg Guaiphenesin 50-400mg Acid source 200-2500mg Alkali source 200-2500mg Flavours/colouring agents 5-200mg Diluent/binder 0-2000mg Lubricants 5-500mg
- Aerosol inhaler (Dry powder inhaler or aqueous pump spray)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition useful in the treatment of respiratory tract disorders. The composition comprises as active ingredients: (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of theses; and (b) a beta 2 agonist, e.g. salbutamol, terbutaline; and (c) an expectorant, e.g. guaiphenesin, sodium citrate, ammonium chloride.
Description
PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCYSTEINE, CARBOCYSTEINE OR ERDO¬ STEINE, IN COMBINATION WITH A BETA 2 AGONIST AND AN EXPECTORANT FOR THE TREAT¬ MENT OF RESPIRATORY TRACT DISORDERS
BACKGROUND OF THE INVENTION
This invention relates to a pharmaceutical composition.
South African Patent Application No. 94/0155 describes and claims a pharmaceutical composition in unit dosage form which comprises a therapeutic dose of acetylcysteine or carbocysteine and a therapeutic dose of terbutaline or pharmaceutically acceptable salt thereof. The composition may be formulated as a capsule, tablet, synip, intravenous solution, nebulising solution, aerosol inhaler, dry powder inhaler or aqueous pump spray. The composition is useful in the treatment of respiratory tract disorders.
South African Patents Nos. 92/1848 and 93/5931 describe simiiar pharmaceutical compositions, save that salbutamol or pharmaceutically acceptable salt thereof are used in place of terbutaline.
SUMMARY OF THE INVENTION
According to the present invention there is provided a pharmaceutical composition comprising as active ingredients:
(a) acetylcysteine, carbocysteine, erdostein or a pharmaceutically acceptable salt oι any of these; and
(b) a beta 2 agonist; and
(c) an expectorant.
DESCRIPTION OF EMBODIMENTS
The pharmaceutical composition of the invention will be provided in the form of dosage units with each unit containing each of the active ingredients. The dosage units may be capsules, tablets, syrups, intravenous solutions, nebulising solutions, aerosol inhalers, dry powder inhalers, or aqueous pump sprays.
Further, the composition will provide each of the active ingredients in therapeutically effective amounts. Thus, the acetylcysteine, carbocysteine, erdosteine or pharmaceutically acceptable salt thereof, will be present in an amount sufficient to produce a mucolytic action; the beta 2 agonist will be present in an amount sufficient to produce a bronchodilating action; and the expectorant will be present in an amount sufficient to produce an expectorant action. The therapeutically effective amount of each active ingredient may be provided in a single dosage unit, e.g. a single tablet, teaspoon or intravenous unit, capsule, or may be provided in more than one dosage unit (multiple units), e.g. more than one tablet, capsule, teaspoon or intravenous unit.
The preferred beta 2 agonist is terbutaline, salbutamol or a pharmaceutically acceptable salt thereof.
The preferred expectorant is guaiphenesin. Other useful expectorants are sodium citrate and ammonium chloride.
The pharmaceutical composition of the invention may be used in the treatment of respiratory tract disorders. The composition has particular use in treating coughs, bronchitis, or chronic pulmonary conditions such as emphysema, chronic bronchitis and bronchicetasis.
The pharmaceutical composition will also contain one or more of the usual excipiεnts which are required to formulate the particular dosage unit.
A preferred composition of the invention contains, as active ingredients, acetylcysteine or a pharmaceutically acceptable salt thereof , terbutaline pharmaceutically acceptable salt thereof / and guaiphenesin.
The following are typical amounts of the active ingredients (preferable amounts being given in brackets) which will be used in the compositions of the invention:
Active Ingredient Amount
Acetylcysteine 50-2000mg (200-600mg)
Erdosteine 25-2000mg
Salbutamol 1-1 Omg (2-4mg)
Terbutaline 1-lOmg (2,5 to 5mg)
Guaiphenesin 50-1000mg (200-400mg)
The same amounts will be used when the active ingredient is in the form of a pharmaceutically acceptable salt.
According to another aspect of the invention there is provided the use of (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and (b) a beta 2 agonist; and (c) an expectorant for the manufacture of a medicament for the treatment of respiratory tract disorders.
According to another aspect of the invention there is provided a method of treatment of a human or animal patient suffering from a respiratory tract disorder comprising administering to said patient: (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and (b) a beta 2 agonist; and (c) an expectorant. The active ingredients are preferably each administered in a therapeutically effective amount.
Examples of suitable compositions of the invention are set out hereinafter.
Capsules mg/capsule
Acetylcysteine 100-2000mg
Terbutaline sulphate 1-lOmg
Guaiphenesin 50-400mg
Diluent/Disintegrant 5-400mg
Glidants 0-25mg
Disintegrants 0-30mg
Tablets mg/tablet
Acetylcysteine 100-2000mg
Terbutaline sulphate lmg-lOmg
Guaiphenesin 50-400mg
Diluent 5-300mg
Disintegrant 2-50mg
Binder 2-100mg
Lubricant l-20mg
Svrup mε/5 or 10ml
Acetylcysteine 100-2000mg
Terbutaline sulphate 1-lOmg
Guaiphenesin 50-400mg
Solvents, solubilisers, stabilisers, alkali 5-1000mg
Colouring agents 0-150mg
Preservatives/Antioxidants l-150mg
Flavours l-200mg
Effervescent tablets mg/tablet
Acetylcysteine 100-2000mg Terbutaline sulphate l-5mg Guaiphenesin 50-400mg Acid source 200-2500mg Alkali source 200-2500mg Flavours/colouring agents 5-200mg Diluent/binder 0-2000mg Lubricants 5-500mg
Nebulising solution
Acetylcysteine 100-2000mg
Terbutaline sulphate l-5mg
Guaiphenesin 10-400mg
Alkali/buffer, isotoxicity agents 5-500mg
Stabilisers, solubilisers O-lOOmg
Aerosol inhaler (Dry powder inhaler or aqueous pump spray)
Acetylcysteine l-2000mg Terbutaline sulphate 100-1000μg Guaiphenesin l-400mg
Granules/Powder for oral solution
Acetylcysteine 100-2000mg
Terbutaline sulphate l-5mg
Guaiphenesin 50-400mg
Binder 0-300mg
Diluent/Glidants 200-5000mg
Flavours/colouring agents l-200mg
Claims
1. A pharmaceutical composition comprising as active ingredients:
(a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and
(b) a beta 2 agonist; and
(c) an expectorant.
2. A pharmaceutical composition according to claim 1 wherein the beta 2 agonist is terbutaline, salbutamol or a pharmaceutically acceptable salt of any of these.
3. A pharmaceutical composition according to claim 1 or claim 2 wherein the expectorant is guaiphenesin, sodium citrate or ammonium chloride.
4. A pharmaceutical composition according to any one of the preceding claims in the form of a dosage unit.
5. A pharmaceutical composition according to claim 4 wherein the dosage unit is a capsule, tablet, syrup, intravenous solution, nebulising solution, aerosol inhaler, dry powder inhaler or aqueous pump spray.
6. A pharmaceutical composition according to any one of the preceding claims which contains, as active ingredients, acetylcysteine or a pharmaceutically acceptable salt thereof, terbutaline or a pharmaceutically acceptable salt thereof and guaiphenesin.
7. A pharmaceutical composition according to any one of the preceding claims for use in the treatment of respiratory tract disorders.
8. A pharmaceutical composition according to claim 7 wherein the respiratory tract disorder is a cough, bronchitis or a chronic pulmonary condition.
9. A pharmaceutical composition according to claim 8 wherein the chronic pulmonary condition is emphysema, chronic bronchitis or bronchiectasis.
10. The use of a combination of
(a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and
(b) a beta 2 agonist; and
(c) an expectorant; for the manufacture of a medicament for the treatment of respiratory tract disorders.
11. The use accordi g to claim 10 wherein the respiratory tract disorder is a cough, bronchitis or a chronic pulmonary condition.
12. The use according to claim 11 wherein the chronic pulmonary condition is emphysema, chronic bronchitis or bronchiectasis.
13. The use according to any one of claims 10 to 12 wherein the combination of acetylcysteine or a pharmaceutically acceptable salt thereof, terbutaline or a pharmaceutically acceptable salt thereof and guaiphenesin.
14. A method of treatment of a human or animal patient suffering from a respiratory tract disorder comprising administering to said patient: (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and
(b) a beta 2 agonist; and (c) an expectorant.
15. A method of treatment according to claim 14 wherein the respiratory tract disorder is a cough, bronchitis or a chronic pulmonary condition.
16. A method of treatment according to claim 15 wherein the chronic pulmonary condition is emphysema, chronic bronchitis or bronchiectasis.
17. A composition comprising:
(a) acetylcysteine, carbocysteine and erdosteine or a pharmaceutically acceptable salt of any of these; and
(b) a beta 2 agonist; and (c) an expectorant; for use in therapy.
18. Products containing
(a) acetylcysteine, carbocysteine and erdosteine or a pharmaceutically acceptable salt of any of these; and
(b) a beta 2 agonist; and
(c) an expectorant; as a combined preparation for simultaneous, separate or sequential use in the treatment of respiratory tract disorders, particularly cough, bronchitis or a chronic pulmonary condition, particularly emphysema, chronic bronchitis or bronchiectasis.
19. A pharmaceutical composition substantially as described herein with reference to any one of the examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU56556/96A AU5655696A (en) | 1995-05-10 | 1996-05-09 | Pharmaceutical composition containing acetylcysteine, carboc ysteine or erdosteine in combination with a beta 2 agonist a nd an expectorant for the treatment of respiratory tract dis orders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA95/3778 | 1995-05-10 | ||
| ZA953778 | 1995-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996035452A1 true WO1996035452A1 (en) | 1996-11-14 |
Family
ID=25585074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1996/001107 Ceased WO1996035452A1 (en) | 1995-05-10 | 1996-05-09 | Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5655696A (en) |
| WO (1) | WO1996035452A1 (en) |
| ZA (1) | ZA963590B (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059500A1 (en) * | 1999-04-06 | 2000-10-12 | Zambon Group S.P.A. | Swallowable tablets with high content of n-acetylcysteine |
| WO2003068206A1 (en) * | 2002-02-13 | 2003-08-21 | Adcock Ingram Intellectual Property (Proprietary) Limited | Pharmaceutical compositions comprising terbutaline or salbutamol in combination with guaiphenesine |
| WO2005013963A1 (en) | 2003-08-06 | 2005-02-17 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| CN1303065C (en) * | 2004-05-20 | 2007-03-07 | 江苏豪森药业股份有限公司 | Ambroxol cysteine analogs and their preparation process and use thereof |
| EP1857106A1 (en) * | 2006-05-16 | 2007-11-21 | Edmond Pharma S.R.L. | Combinations of erdosteine and beta-2 agonists for treating COPD |
| EP2068903A4 (en) * | 2006-10-03 | 2010-11-03 | Galleon Pharmaceuticals Inc | S-nitrosothiol compounds and related derivatives |
| EP1940369A4 (en) * | 2005-09-20 | 2011-01-26 | Galleon Pharmaceuticals Inc | Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm |
| WO2011030163A1 (en) * | 2009-09-12 | 2011-03-17 | Reckitt Benckiser Llc | Use of guaifenesin for inhibiting mucin secretion |
| WO2011142677A1 (en) * | 2010-05-11 | 2011-11-17 | Breathe Easy Ltd | Methods and compositions for the treatment of lung disorders |
| US20160120899A1 (en) * | 2009-06-16 | 2016-05-05 | Infirst Healthcare Limited | Drug Combinations and Uses in Treating a Coughing Condition |
| US9675618B2 (en) | 2009-06-16 | 2017-06-13 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9700561B2 (en) | 2009-06-16 | 2017-07-11 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| WO2019212427A3 (en) * | 2017-12-30 | 2019-11-28 | Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi | Compositions comprising erdosteine and ascorbic acid |
| CN113018444A (en) * | 2020-01-09 | 2021-06-25 | 海南斯达制药有限公司 | Pharmaceutical composition for treating respiratory system diseases and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991017746A1 (en) * | 1990-05-21 | 1991-11-28 | Norwich Eaton Pharmaceuticals, Inc. | The use of phenylpropanolamine as a mucus secretagogue in the upper airways |
| ZA921848B (en) * | 1991-05-10 | 1992-11-25 | South African Druggists Ltd | Pharmaceutical composition |
| EP0521388A1 (en) * | 1991-07-01 | 1993-01-07 | Gerhard Dr. Gergely | Process for the preparation of a pharmaceutical preparation containing at least two different actives and use thereof |
| ZA935931B (en) * | 1992-08-18 | 1994-03-07 | South African Druggists Ltd | Pharmaceutical composition |
| ZA94155B (en) * | 1992-11-06 | 1995-07-11 | Adcock Ingram Pharma | Pharmaceutical composition |
| DE19502566A1 (en) * | 1994-01-31 | 1995-08-03 | Zambon Int Pharma | N-acetyl-cysteine-containing pharmaceutical compositions |
-
1996
- 1996-05-07 ZA ZA963590A patent/ZA963590B/en unknown
- 1996-05-09 AU AU56556/96A patent/AU5655696A/en not_active Abandoned
- 1996-05-09 WO PCT/GB1996/001107 patent/WO1996035452A1/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991017746A1 (en) * | 1990-05-21 | 1991-11-28 | Norwich Eaton Pharmaceuticals, Inc. | The use of phenylpropanolamine as a mucus secretagogue in the upper airways |
| ZA921848B (en) * | 1991-05-10 | 1992-11-25 | South African Druggists Ltd | Pharmaceutical composition |
| EP0521388A1 (en) * | 1991-07-01 | 1993-01-07 | Gerhard Dr. Gergely | Process for the preparation of a pharmaceutical preparation containing at least two different actives and use thereof |
| ZA935931B (en) * | 1992-08-18 | 1994-03-07 | South African Druggists Ltd | Pharmaceutical composition |
| ZA94155B (en) * | 1992-11-06 | 1995-07-11 | Adcock Ingram Pharma | Pharmaceutical composition |
| DE19502566A1 (en) * | 1994-01-31 | 1995-08-03 | Zambon Int Pharma | N-acetyl-cysteine-containing pharmaceutical compositions |
Non-Patent Citations (8)
| Title |
|---|
| A. MINETTE: "Conclusions of an international symposium held at Aachen on 4 and 5 May about mucolytic agents, especially oral acetylcysteine", REV INST HYG MINES, vol. 34, no. 3, 1979, pages 159 - 165, XP002014822 * |
| C. MAAYAN ET AL.: "Immediate effect of various treatments on lung function in infants with cystic fibrosis", RESPIRATION, vol. 55, no. 3, 1989, pages 144 - 151, XP002014824 * |
| D. OLIVIERI: "Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis", RESPIRATION, vol. 58, no. 2, 1991, pages 91 - 94, XP002014823 * |
| DATABASE WPI Week 9315, Derwent World Patents Index; AN 93-126431, XP002014828 * |
| DATABASE WPI Week 9428, Derwent World Patents Index; AN 94-235044, XP002014827 * |
| DATABASE WPI Week 9548, Derwent World Patents Index; AN 95-374034, XP002014829 * |
| M. DEL DONNO ET AL.: "Efficacy of clenbuterol and ambroxol alone and in association on tracheal mucus velocity in chronic bronchitis", EUR RESPIR J, vol. 1, no. suppl. 2, 1988, pages 308s, XP002014825 * |
| W. COUET ET AL.: "Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation", INT J CLIN PHARMACOL THER TOXICOL, vol. 27, no. 9, 1989, pages 467 - 472, XP002014826 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059500A1 (en) * | 1999-04-06 | 2000-10-12 | Zambon Group S.P.A. | Swallowable tablets with high content of n-acetylcysteine |
| WO2003068206A1 (en) * | 2002-02-13 | 2003-08-21 | Adcock Ingram Intellectual Property (Proprietary) Limited | Pharmaceutical compositions comprising terbutaline or salbutamol in combination with guaiphenesine |
| WO2005013963A1 (en) | 2003-08-06 | 2005-02-17 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| CN1303065C (en) * | 2004-05-20 | 2007-03-07 | 江苏豪森药业股份有限公司 | Ambroxol cysteine analogs and their preparation process and use thereof |
| EP1940369A4 (en) * | 2005-09-20 | 2011-01-26 | Galleon Pharmaceuticals Inc | Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm |
| EP1857106A1 (en) * | 2006-05-16 | 2007-11-21 | Edmond Pharma S.R.L. | Combinations of erdosteine and beta-2 agonists for treating COPD |
| WO2007131592A1 (en) * | 2006-05-16 | 2007-11-22 | Edmond Pharma S.R.L. | Combinations of erdosteine and beta-2 agonists for treating copd |
| EP2068903A4 (en) * | 2006-10-03 | 2010-11-03 | Galleon Pharmaceuticals Inc | S-nitrosothiol compounds and related derivatives |
| US9675618B2 (en) | 2009-06-16 | 2017-06-13 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US20160120899A1 (en) * | 2009-06-16 | 2016-05-05 | Infirst Healthcare Limited | Drug Combinations and Uses in Treating a Coughing Condition |
| US9700561B2 (en) | 2009-06-16 | 2017-07-11 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| AU2010294008B2 (en) * | 2009-09-12 | 2014-08-14 | Rb Health (Us) Llc | Use of guaifenesin for inhibiting mucin secretion |
| WO2011030163A1 (en) * | 2009-09-12 | 2011-03-17 | Reckitt Benckiser Llc | Use of guaifenesin for inhibiting mucin secretion |
| WO2011142677A1 (en) * | 2010-05-11 | 2011-11-17 | Breathe Easy Ltd | Methods and compositions for the treatment of lung disorders |
| WO2019212427A3 (en) * | 2017-12-30 | 2019-11-28 | Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi | Compositions comprising erdosteine and ascorbic acid |
| CN113018444A (en) * | 2020-01-09 | 2021-06-25 | 海南斯达制药有限公司 | Pharmaceutical composition for treating respiratory system diseases and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA963590B (en) | 1996-11-19 |
| AU5655696A (en) | 1996-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK18695A (en) | Inhalation medicaments for treating respiratory disorders | |
| WO1996035452A1 (en) | Pharmaceutical composition containing acetylcysteine, carbocysteine or erdosteine in combination with a beta 2 agonist and an expectorant for the treatment of respiratory tract disorders | |
| CA2277365A1 (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 | |
| BG102689A (en) | PHARMACEUTICAL AEROSOL COMPOSITION FOR USE IN TREATMENT OF RESPIRATORY DISORDERS | |
| CA2334411A1 (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma | |
| EA022840B1 (en) | Pharmaceutical composition, kit, use thereof and method for prophylactics and treatment of a symptom, condition or disease associated with infection by an influenza virus | |
| WO1999040883A3 (en) | Compositions and methods for the treatment of cystic fibrosis | |
| US5753712A (en) | Treatment of migraine headaches and formulations | |
| AU685741B2 (en) | Sprayable analgesic composition and method of use | |
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| JP2003503453A5 (en) | Synergistic composition comprising gabapentin and pregabalin | |
| CA2506962A1 (en) | Synergistic combination comprising roflumilast and formoterol | |
| WO1995022324A1 (en) | Treatment of migraine headaches and formulations | |
| WO1995005816A1 (en) | Sodium cromoglycate for the treatment of upper respiratory tract infections | |
| JPH01228912A (en) | Prevention of pneumocystis carinii pneumonia using pentamidine in aerozol form | |
| HUT64216A (en) | Process for producing cough diminishing medical preparative containing dextrometorphane | |
| CA2506956A1 (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
| MXPA03007017A (en) | Medicaments. | |
| EP1249242B1 (en) | Natural-Phytotherapic composition based on hydroglyceric extracts for aerosol therapy | |
| WO2003068206A1 (en) | Pharmaceutical compositions comprising terbutaline or salbutamol in combination with guaiphenesine | |
| JP2000229853A (en) | Menstrual pain improving composition | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| CA2456721A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| JP2002370977A (en) | Topical composition | |
| AU2001268760B2 (en) | Medicaments for treating colics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |